Pharmacoeconomic Analysis of Influenza Vaccine Prophylaxis Using Trivalent Vaccine in the Conditions of Healthcare in Kazakhstan

Authors

  • Kamila Gaitova Республиканский центр развития здравоохранения
  • Ерсултан Тамабеков Республиканский центр развития здравоохранения
  • Адлет Табаров Республиканский центр развития здравоохранения
  • Заид Жолдасов Республиканский центр развития здравоохранения
  • Ерканат Бейсахметов Республиканский центр развития здравоохранения
  • Жандос Салпынов Республиканский центр развития здравоохранения
  • Анара Жусупова Республиканский центр развития здравоохранения

Keywords:

influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults

Abstract

Abstract

The primary purpose: To assess the clinical and economic effectiveness of influenza vaccination with population coverage of 40% compared with the absence of vaccination and at 10% current coverage in the health system of the Republic of Kazakhstan.

The secondary purpose: To carry out an assessment of clinical and economic effectiveness of influenza vaccination in school-aged children compared with the absence of vaccination

Methods. A decision-making model was developed to assess the economic and clinical effectiveness of influenza vaccination in children and adults. Pharmacoeconomic analysis of influenza vaccine prophylaxis with the use of the trivalent vaccine Grippol® plus in the healthcare environment of Kazakhstan. The creation of the model was based on the description of the influenza progression in vaccinated and unvaccinated children and adults depending on the possible variants of its progression. In addition, to calculate QALY loss, the effect of disease on a patient’s quality of life was taken into account.

Results. According to the budget impact analysis results, if school-aged children are vaccinated with coverage of 80%, the total cost stands at 7 140 383 360.87 tenges. In the case of refusal of vaccination among school – aged children, the total treatment costs for children with influenza will account for 8 589 133 135,95 tenges, with expenditures increased by 1 448 749 775,08 tenges. If adults (18 years of age and older) are vaccinated and 10% of the population is covered by immunization, the total cost will be 27 791 126 613.76 and 26 848 387 939.88 tenges, respectively. In the case of non-vaccination in adults, the total costs for the treatment of influenza will be 28 105 372 838,39 tenges, which is higher by 314 246 224,63 tenges than in the case of the population’s vaccination coverage of 10%, and by 1 256 984 898,51 tenges with vaccination coverage of 40%.

Conclusion. In general, children and adults’ vaccination is not only a cost-effective but also a cost-saving method of preventing influenza in the health care system of Kazakhstan.

Keywords: influenza vaccines, vaccination, clinical effectiveness, cost-effectiveness, cost-utility, children, adults.

Published

2023-01-08

Issue

Section

Статьи

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.